Novartis gets majority stake in Idenix for CHF352; deal later restructured
- Includes Contract
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.